影像组学风险评分可能成为预测异柠檬酸脱氢酶野生型低级别胶质瘤生存的影像生物标志物
回顾性分析117例IDH野生型低级别胶质瘤患者术前MRI,提取182个影像组学特征,用LASSO和弹性网络构建影像组学风险评分(RRS)。RRS可独立预测总生存(HR 9.479和6.148),将RRS加入临床特征后iAUC从0.726升至0.780-0.797,并在33例TCGA外部验证队列中验证。
要点
- IDH野生型组织学II-III级低级别胶质瘤结局异质,需进一步风险分层。
- MRI影像组学风险评分可独立预测总生存,HR为6.148-9.479。
- 影像组学风险评分加入临床特征后iAUC由0.726升至0.780-0.797。
核心结论
- 影像组学有潜力实现无创风险分层,与临床特征整合后可改善IDH野生型低级别胶质瘤患者的总生存预测。
研究设计与样本
- 回顾性分析2007年1月至2018年2月117例IDH野生型低级别胶质瘤患者的术前MRI。
- 外部验证队列为来自癌症基因组图谱(The Cancer Genome Atlas)的33例患者。
- 共提取182个影像组学特征,采用LASSO和弹性网络构建总生存的影像组学风险评分(RRS)。
- 进行包含临床特征和RRS的多变量Cox回归分析,并计算含与不含RRS模型的iAUC进行比较。
诊断标准与关键数值
- LASSO来源的RRS独立预测生存的HR为9.479(95%CI 3.220-27.847)。
- 弹性网络来源的RRS独立预测生存的HR为6.148(95%CI 3.009-12.563)。
- 含RRS模型的iAUC由0.726升至0.780-0.797,并获外部验证。
- RRS在验证队列中将IDH野生型低级别胶质瘤分为生存显著不同的组。
临床应用与阅片要点
- 原文结论认为影像组学有潜力用于无创风险分层,与临床特征整合可改善总生存预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Isocitrate dehydrogenase wild-type (IDHwt) lower-grade gliomas of histologic grades II and III follow heterogeneous clinical outcomes, which necessitates risk stratification. We aimed to evaluate whether radiomics from MRI would allow prediction of overall survival in patients with IDHwt lower-grade gliomas and to investigate the added prognostic value of radiomics over clinical features.
METHODS: Preoperative MRIs of 117 patients with IDHwt lower-grade gliomas from January 2007 to February 2018 were retrospectively analyzed. The external validation cohort consisted of 33 patients from The Cancer Genome Atlas. A total of 182 radiomic features were extracted. Radiomics risk scores (RRSs) for overall survival were derived from the least absolute shrinkage and selection operator (LASSO) and elastic net. Multivariable Cox regression analyses, including clinical features and RRSs, were performed. The integrated areas under the receiver operating characteristic curves (iAUCs) from models with and without RRSs were calculated for comparisons. The prognostic value of RRS was assessed in the validation cohort.
RESULTS: The RRS derived from LASSO and elastic net independently predicted survival with hazard ratios of 9.479 (95% confidence interval [CI], 3.220-27.847) and 6.148 (95% CI, 3.009-12.563), respectively. Those RRSs enhanced model performance for predicting overall survival (iAUC increased to 0.780-0.797 from 0.726), which was externally validated. The RRSs stratified IDHwt lower-grade gliomas in the validation cohort with significantly different survival.
CONCLUSION: Radiomics has the potential for noninvasive risk stratification and can improve prediction of overall survival in patients with IDHwt lower-grade gliomas when integrated with clinical features.
KEY POINTS: • Isocitrate dehydrogenase wild-type lower-grade gliomas with histologic grades II and III follow heterogeneous clinical outcomes, which necessitates further risk stratification. • Radiomics risk scores derived from MRI independently predict survival even after incorporating strong clinical prognostic features (hazard ratios 6.148-9.479). • Radiomics risk scores derived from MRI have the potential to improve survival prediction when added to clinical features (integrated areas under the receiver operating characteristic curves increased from 0.726 to 0.780-0.797).
引用
- Park CJ, Han K, Kim H, et al. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas. Eur Radiol. 2020. PMID: 32740813. doi:10.1007/s00330-020-07089-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。